Technical Analysis for CAPR - Capricor Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 0.3162 -1.19% 0.00
CAPR closed down 1.19 percent on Monday, May 20, 2019, on 79 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
3 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical CAPR trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Volume Surge Other -1.19%

Older signals for CAPR ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Analyze My Stocks!
Configure default chart indicators
Basic chart:

Profile
Capricor Therapeutics, Inc., a biotechnology company, is focused on the development of novel therapeutics to prevent and treat cardiovascular diseases. Its lead product candidates include CAP-1002 and Cenderitide. The company was founded in 2005 and is based in Beverly Hills, California.
Biotechnology Life Sciences Cardiovascular Diseases Regulus Therapeutics Two River
Is CAPR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
May 14 Capricor Therapeutics, Inc. (CAPR) CEO Linda Marbán on Q1 2019 Results - Earnings Call Transcript
May 13 Capricor Therapeutics (CAPR) Reports Q1 Loss, Lags Revenue Estimates
May 13 Data readout from mid-stage study of Capricor's CAP-1002 expected next quarter; shares up 5% after hours
May 13 Capricor: 1Q Earnings Snapshot
May 13 Capricor Therapeutics beats by $0.03, misses on revenue
May 13 Capricor Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 13 Capricor Therapeutics, Inc. to Host Earnings Call
May 6 Capricor Therapeutics to Present First Quarter 2019 Financial Results and Recent Corporate Update on May 13
Apr 29 PTC's Translarna OK'd in Brazil for DMD
Apr 8 Audentes launches programs in DMD and DM1
See more CAPR news...
Indicators
Indicator Value
52 Week High 1.58
52 Week Low 0.31
Average Volume 240,307
200-Day Moving Average 0.7259
50-Day Moving Average 0.5066
20-Day Moving Average 0.4359
10-Day Moving Average 0.3902
Average True Range 0.0446
ADX 36.26
+DI 6.4831
-DI 29.5182
Chandelier Exit (Long, 3 ATRs ) 0.4161000000000001
Chandelier Exit (Short, 3 ATRs ) 0.4438
Upper Bollinger Band 0.5446
Lower Bollinger Band 0.3272
Percent B (%b) -0.05
BandWidth 49.873824
MACD Line -0.0475
MACD Signal Line -0.0357
MACD Histogram -0.0118
Fundamentals Value
Market Cap 7.43 Million
Num Shares 23.5 Million
EPS -0.82
Price-to-Earnings (P/E) Ratio -0.39
Price-to-Sales 15.44
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.38
Resistance 3 (R3) 0.38 0.37 0.37
Resistance 2 (R2) 0.37 0.35 0.36 0.36
Resistance 1 (R1) 0.34 0.34 0.33 0.34 0.36
Pivot Point 0.33 0.33 0.32 0.32 0.33
Support 1 (S1) 0.30 0.31 0.29 0.30 0.27
Support 2 (S2) 0.29 0.30 0.28 0.27
Support 3 (S3) 0.26 0.29 0.27
Support 4 (S4) 0.26